HEADER OXIDOREDUCTASE 01-FEB-10 3LN3 TITLE CRYSTAL STRUCTURE OF PUTATIVE REDUCTASE (NP_038806.2) FROM MUS TITLE 2 MUSCULUS AT 1.18 A RESOLUTION COMPND MOL_ID: 1; COMPND 2 MOLECULE: DIHYDRODIOL DEHYDROGENASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: PUTATIVE REDUCTASE; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: MUS MUSCULUS; SOURCE 3 ORGANISM_COMMON: MOUSE; SOURCE 4 ORGANISM_TAXID: 10090; SOURCE 5 GENE: AKR1C13, DDH; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: HK100; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: SPEEDET KEYWDS PUTATIVE REDUCTASE, STRUCTURAL GENOMICS, JOINT CENTER FOR STRUCTURAL KEYWDS 2 GENOMICS, JCSG, PROTEIN STRUCTURE INITIATIVE, PSI-2, OXIDOREDUCTASE EXPDTA X-RAY DIFFRACTION AUTHOR JOINT CENTER FOR STRUCTURAL GENOMICS (JCSG) REVDAT 3 17-JUL-19 3LN3 1 REMARK LINK REVDAT 2 01-NOV-17 3LN3 1 REMARK REVDAT 1 16-FEB-10 3LN3 0 JRNL AUTH JOINT CENTER FOR STRUCTURAL GENOMICS (JCSG) JRNL TITL CRYSTAL STRUCTURE OF PUTATIVE REDUCTASE (NP_038806.2) FROM JRNL TITL 2 MUS MUSCULUS AT 1.18 A RESOLUTION JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.18 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0053 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD WITH PHASES REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.18 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 28.90 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.8 REMARK 3 NUMBER OF REFLECTIONS : 110769 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.132 REMARK 3 R VALUE (WORKING SET) : 0.131 REMARK 3 FREE R VALUE : 0.156 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 5543 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.18 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.21 REMARK 3 REFLECTION IN BIN (WORKING SET) : 6249 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 78.52 REMARK 3 BIN R VALUE (WORKING SET) : 0.2270 REMARK 3 BIN FREE R VALUE SET COUNT : 312 REMARK 3 BIN FREE R VALUE : 0.2800 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2608 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 67 REMARK 3 SOLVENT ATOMS : 395 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 7.92 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 12.41 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.03000 REMARK 3 B22 (A**2) : 0.39000 REMARK 3 B33 (A**2) : -0.39000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.21000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.033 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.033 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.021 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 1.046 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.978 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.973 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2960 ; 0.014 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 2016 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 4081 ; 1.827 ; 2.036 REMARK 3 BOND ANGLES OTHERS (DEGREES): 4980 ; 0.992 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 382 ; 5.467 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 132 ;35.170 ;24.697 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 569 ;13.812 ;15.272 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 16 ;16.205 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 473 ; 0.200 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3205 ; 0.010 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 553 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1708 ; 1.753 ; 2.000 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 672 ; 0.813 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2811 ; 2.466 ; 3.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1252 ; 2.533 ; 2.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1238 ; 3.650 ; 3.000 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): 4976 ; 1.365 ; 3.000 REMARK 3 SPHERICITY; FREE ATOMS (A**2): 405 ; 7.262 ; 3.000 REMARK 3 SPHERICITY; BONDED ATOMS (A**2): 4882 ; 2.979 ; 3.000 REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS 1.HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. REMARK 3 2.A MET-INHIBITION PROTOCOL WAS USED FOR SELENOMETHIONINE REMARK 3 INCORPORATION DURING PROTEIN EXPRESSION. THE OCCUPANCY OF THE SE REMARK 3 ATOMS IN THE MSE RESIDUES WAS REDUCED TO 0.75 FOR THE REDUCED REMARK 3 SCATTERING POWER DUE TO PARTIAL S-MET INCORPORATION. 3.SULFATE REMARK 3 (SO4) FROM THE CRYSTALLIZATION SOLUTION HAS BEEN MODELED IN THE REMARK 3 SOLVENT STRUCTURE. 4.ENDOGENOUS NICOTINAMIDE ADENINE REMARK 3 DINUCLEOTIDE (NAD), WHICH IS THE EXPECTED COFACTOR FOR THIS REMARK 3 PROTEIN, HAS BEEN MODELED AT THE PUTATIVE ACTIVE SITE. THE NAD REMARK 3 SHOWS SOME DISORDER IN THE STRUCTURE. 5.(4R)-2-METHYLPENTANE-2,4- REMARK 3 DIOL (MRD), WHICH MAY BE A SUBSTRATE MIMIC, HAS BEEN MODELED IN REMARK 3 THE PUTATIVE ACTIVE SITE BASED ON THE ELECTRON DENSITY. HOWEVER, REMARK 3 IT IS POSSIBLE THAT THIS MAY BE SOME OTHER COMPOUND. 6.THE REMARK 3 PROTEIN WAS SUBJECTED TO REDUCTIVE METHYLATION PRIOR TO REMARK 3 CRYSTALLIZATION. LYSINE 84 APPEARS TO HAVE BEEN PROTECTED FROM REMARK 3 REDUCTIVE METHYLATION AND WAS MODELED AS LYSINE. ALL OTHER REMARK 3 LYSINES HAVE BEEN MODELED AS N-DIMETHYL-LYSINE (MLY). REMARK 4 REMARK 4 3LN3 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 04-FEB-10. REMARK 100 THE DEPOSITION ID IS D_1000057481. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 05-NOV-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97931 REMARK 200 MONOCHROMATOR : DOUBLE CRYSTAL MONOCHROMATOR REMARK 200 OPTICS : FLAT COLLIMATING MIRROR, TOROID REMARK 200 FOCUSING MIRROR REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 325 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 110769 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.180 REMARK 200 RESOLUTION RANGE LOW (A) : 28.895 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.0 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.06400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 6.2300 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.18 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.22 REMARK 200 COMPLETENESS FOR SHELL (%) : 67.4 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.45700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: SAD REMARK 200 SOFTWARE USED: SHELX, SHELXD, AUTOSHARP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.17 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.29 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 2.4000M AMMONIUM SULFATE, 0.1M TRIS PH REMARK 280 8.0, NANODROP, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 78.75300 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 23.60300 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 78.75300 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 23.60300 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: CRYSTAL PACKING ANALYSIS SUPPORTS THE ASSIGNMENT OF A REMARK 300 MONOMER AS THE SIGNIFICANT OLIGOMERIC FORM IN SOLUTION. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5650 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 26870 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -104.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 0 REMARK 465 MSE A 1 REMARK 465 SER A 2 REMARK 465 SER A 3 REMARK 465 MLY A 4 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 5 CB CG CD OE1 NE2 REMARK 470 MLY A 101 CE NZ CH1 CH2 REMARK 470 GLU A 133 CD OE1 OE2 REMARK 470 GLN A 134 CG CD OE1 NE2 REMARK 470 MLY A 136 CE NZ CH1 CH2 REMARK 470 MLY A 246 CD CE NZ CH1 CH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OD1 ASP A 204 O HOH A 607 2.17 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 557 O HOH A 676 1554 2.05 REMARK 500 CH2 MLY A 33 O HOH A 574 4555 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 221 164.75 71.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 324 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 325 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 326 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NAD A 327 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MRD A 328 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 400045 RELATED DB: TARGETDB REMARK 999 REMARK 999 SEQUENCE REMARK 999 1.THIS CONSTRUCT WAS EXPRESSED WITH A PURIFICATION TAG REMARK 999 MGSDKIHHHHHHENLYFQG. THE TAG WAS REMOVED WITH TEV PROTEASE LEAVING REMARK 999 ONLY A GLYCINE (0) FOLLOWED BY THE TARGET SEQUENCE. 2.THE PROTEIN REMARK 999 WAS REDUCTIVELY METHYLATED PRIOR TO CRYSTALLIZATION. DBREF 3LN3 A 1 323 UNP Q54A37 Q54A37_MOUSE 1 323 SEQADV 3LN3 GLY A 0 UNP Q54A37 EXPRESSION TAG SEQRES 1 A 324 GLY MSE SER SER MLY GLN HIS CYS VAL MLY LEU ASN ASP SEQRES 2 A 324 GLY HIS LEU ILE PRO ALA LEU GLY PHE GLY THR TYR MLY SEQRES 3 A 324 PRO MLY GLU VAL PRO MLY SER MLY SER LEU GLU ALA ALA SEQRES 4 A 324 CYS LEU ALA LEU ASP VAL GLY TYR ARG HIS VAL ASP THR SEQRES 5 A 324 ALA TYR ALA TYR GLN VAL GLU GLU GLU ILE GLY GLN ALA SEQRES 6 A 324 ILE GLN SER MLY ILE MLY ALA GLY VAL VAL MLY ARG GLU SEQRES 7 A 324 ASP LEU PHE VAL THR THR LYS LEU TRP CYS THR CYS PHE SEQRES 8 A 324 ARG PRO GLU LEU VAL MLY PRO ALA LEU GLU MLY SER LEU SEQRES 9 A 324 MLY MLY LEU GLN LEU ASP TYR VAL ASP LEU TYR ILE MSE SEQRES 10 A 324 HIS TYR PRO VAL PRO MSE MLY SER GLY ASP ASN ASP PHE SEQRES 11 A 324 PRO VAL ASN GLU GLN GLY MLY SER LEU LEU ASP THR VAL SEQRES 12 A 324 ASP PHE CYS ASP THR TRP GLU ARG LEU GLU GLU CYS MLY SEQRES 13 A 324 ASP ALA GLY LEU VAL MLY SER ILE GLY VAL SER ASN PHE SEQRES 14 A 324 ASN HIS ARG GLN LEU GLU ARG ILE LEU ASN MLY PRO GLY SEQRES 15 A 324 LEU MLY TYR MLY PRO VAL CYS ASN GLN VAL GLU CYS HIS SEQRES 16 A 324 LEU TYR LEU ASN GLN ARG MLY LEU LEU ASP TYR CYS GLU SEQRES 17 A 324 SER MLY ASP ILE VAL LEU VAL ALA TYR GLY ALA LEU GLY SEQRES 18 A 324 THR GLN ARG TYR MLY GLU TRP VAL ASP GLN ASN SER PRO SEQRES 19 A 324 VAL LEU LEU ASN ASP PRO VAL LEU CYS ASP VAL ALA MLY SEQRES 20 A 324 MLY ASN MLY ARG SER PRO ALA LEU ILE ALA LEU ARG TYR SEQRES 21 A 324 LEU ILE GLN ARG GLY ILE VAL PRO LEU ALA GLN SER PHE SEQRES 22 A 324 MLY GLU ASN GLU MSE ARG GLU ASN LEU GLN VAL PHE GLY SEQRES 23 A 324 PHE GLN LEU SER PRO GLU ASP MSE MLY THR LEU ASP GLY SEQRES 24 A 324 LEU ASN MLY ASN PHE ARG TYR LEU PRO ALA GLU PHE LEU SEQRES 25 A 324 VAL ASP HIS PRO GLU TYR PRO PHE VAL GLU GLU TYR MODRES 3LN3 MLY A 9 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 25 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 27 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 31 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 33 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 68 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 70 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 75 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 96 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 101 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 104 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 105 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MSE A 116 MET SELENOMETHIONINE MODRES 3LN3 MSE A 122 MET SELENOMETHIONINE MODRES 3LN3 MLY A 123 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 136 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 155 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 161 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 179 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 183 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 185 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 201 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 209 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 225 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 246 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 247 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 249 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 273 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MSE A 277 MET SELENOMETHIONINE MODRES 3LN3 MSE A 293 MET SELENOMETHIONINE MODRES 3LN3 MLY A 294 LYS N-DIMETHYL-LYSINE MODRES 3LN3 MLY A 301 LYS N-DIMETHYL-LYSINE HET MLY A 9 11 HET MLY A 25 11 HET MLY A 27 19 HET MLY A 31 11 HET MLY A 33 19 HET MLY A 68 11 HET MLY A 70 11 HET MLY A 75 11 HET MLY A 96 19 HET MLY A 101 11 HET MLY A 104 19 HET MLY A 105 11 HET MSE A 116 8 HET MSE A 122 13 HET MLY A 123 11 HET MLY A 136 7 HET MLY A 155 11 HET MLY A 161 11 HET MLY A 179 11 HET MLY A 183 19 HET MLY A 185 11 HET MLY A 201 11 HET MLY A 209 11 HET MLY A 225 11 HET MLY A 246 9 HET MLY A 247 19 HET MLY A 249 11 HET MLY A 273 11 HET MSE A 277 8 HET MSE A 293 8 HET MLY A 294 11 HET MLY A 301 11 HET SO4 A 324 5 HET SO4 A 325 5 HET SO4 A 326 5 HET NAD A 327 44 HET MRD A 328 8 HETNAM MLY N-DIMETHYL-LYSINE HETNAM MSE SELENOMETHIONINE HETNAM SO4 SULFATE ION HETNAM NAD NICOTINAMIDE-ADENINE-DINUCLEOTIDE HETNAM MRD (4R)-2-METHYLPENTANE-2,4-DIOL FORMUL 1 MLY 28(C8 H18 N2 O2) FORMUL 1 MSE 4(C5 H11 N O2 SE) FORMUL 2 SO4 3(O4 S 2-) FORMUL 5 NAD C21 H27 N7 O14 P2 FORMUL 6 MRD C6 H14 O2 FORMUL 7 HOH *395(H2 O) HELIX 1 1 PRO A 30 GLY A 45 1 16 HELIX 2 2 ALA A 52 GLN A 56 5 5 HELIX 3 3 VAL A 57 ALA A 71 1 15 HELIX 4 4 MLY A 75 LEU A 79 5 5 HELIX 5 5 TRP A 86 PHE A 90 5 5 HELIX 6 6 ARG A 91 GLU A 93 5 3 HELIX 7 7 LEU A 94 GLN A 107 1 14 HELIX 8 8 ASP A 143 ALA A 157 1 15 HELIX 9 9 ASN A 169 ASN A 178 1 10 HELIX 10 10 GLN A 199 MLY A 209 1 11 HELIX 11 11 VAL A 234 ASN A 237 5 4 HELIX 12 12 ASP A 238 MLY A 249 1 12 HELIX 13 13 SER A 251 ARG A 263 1 13 HELIX 14 14 MLY A 273 LEU A 281 1 9 HELIX 15 15 GLN A 282 PHE A 286 5 5 HELIX 16 16 SER A 289 GLY A 298 1 10 HELIX 17 17 ALA A 308 VAL A 312 5 5 SHEET 1 A 2 CYS A 7 MLY A 9 0 SHEET 2 A 2 LEU A 15 PRO A 17 -1 O ILE A 16 N VAL A 8 SHEET 1 B 9 GLY A 20 GLY A 22 0 SHEET 2 B 9 HIS A 48 ASP A 50 1 O ASP A 50 N PHE A 21 SHEET 3 B 9 PHE A 80 LEU A 85 1 O PHE A 80 N VAL A 49 SHEET 4 B 9 VAL A 111 MSE A 116 1 O ILE A 115 N LEU A 85 SHEET 5 B 9 VAL A 160 SER A 166 1 O MLY A 161 N VAL A 111 SHEET 6 B 9 CYS A 188 GLU A 192 1 O GLN A 190 N VAL A 165 SHEET 7 B 9 VAL A 212 TYR A 216 1 O VAL A 214 N VAL A 191 SHEET 8 B 9 VAL A 266 ALA A 269 1 O LEU A 268 N ALA A 215 SHEET 9 B 9 GLY A 20 GLY A 22 1 N GLY A 20 O PRO A 267 LINK C VAL A 8 N MLY A 9 1555 1555 1.33 LINK C MLY A 9 N LEU A 10 1555 1555 1.32 LINK C TYR A 24 N MLY A 25 1555 1555 1.33 LINK C MLY A 25 N PRO A 26 1555 1555 1.34 LINK C PRO A 26 N MLY A 27 1555 1555 1.33 LINK C MLY A 27 N GLU A 28 1555 1555 1.33 LINK C PRO A 30 N MLY A 31 1555 1555 1.33 LINK C MLY A 31 N SER A 32 1555 1555 1.33 LINK C SER A 32 N MLY A 33 1555 1555 1.33 LINK C MLY A 33 N SER A 34 1555 1555 1.32 LINK C SER A 67 N MLY A 68 1555 1555 1.33 LINK C MLY A 68 N ILE A 69 1555 1555 1.33 LINK C ILE A 69 N MLY A 70 1555 1555 1.33 LINK C MLY A 70 N ALA A 71 1555 1555 1.33 LINK C VAL A 74 N MLY A 75 1555 1555 1.33 LINK C MLY A 75 N ARG A 76 1555 1555 1.33 LINK C VAL A 95 N MLY A 96 1555 1555 1.34 LINK C MLY A 96 N PRO A 97 1555 1555 1.34 LINK C GLU A 100 N MLY A 101 1555 1555 1.33 LINK C MLY A 101 N SER A 102 1555 1555 1.33 LINK C LEU A 103 N MLY A 104 1555 1555 1.33 LINK C MLY A 104 N MLY A 105 1555 1555 1.34 LINK C MLY A 105 N LEU A 106 1555 1555 1.33 LINK C ILE A 115 N MSE A 116 1555 1555 1.33 LINK C MSE A 116 N HIS A 117 1555 1555 1.34 LINK C PRO A 121 N MSE A 122 1555 1555 1.33 LINK C MSE A 122 N MLY A 123 1555 1555 1.32 LINK C MLY A 123 N SER A 124 1555 1555 1.33 LINK C GLY A 135 N MLY A 136 1555 1555 1.34 LINK C MLY A 136 N SER A 137 1555 1555 1.33 LINK C CYS A 154 N MLY A 155 1555 1555 1.32 LINK C MLY A 155 N ASP A 156 1555 1555 1.32 LINK C VAL A 160 N MLY A 161 1555 1555 1.34 LINK C MLY A 161 N SER A 162 1555 1555 1.33 LINK C ASN A 178 N MLY A 179 1555 1555 1.32 LINK C MLY A 179 N PRO A 180 1555 1555 1.35 LINK C LEU A 182 N MLY A 183 1555 1555 1.33 LINK C MLY A 183 N TYR A 184 1555 1555 1.34 LINK C TYR A 184 N MLY A 185 1555 1555 1.33 LINK C MLY A 185 N PRO A 186 1555 1555 1.33 LINK C ARG A 200 N MLY A 201 1555 1555 1.33 LINK C MLY A 201 N LEU A 202 1555 1555 1.32 LINK C SER A 208 N MLY A 209 1555 1555 1.33 LINK C MLY A 209 N ASP A 210 1555 1555 1.33 LINK C TYR A 224 N MLY A 225 1555 1555 1.33 LINK C MLY A 225 N GLU A 226 1555 1555 1.33 LINK C ALA A 245 N MLY A 246 1555 1555 1.33 LINK C MLY A 246 N MLY A 247 1555 1555 1.33 LINK C MLY A 247 N ASN A 248 1555 1555 1.34 LINK C ASN A 248 N MLY A 249 1555 1555 1.33 LINK C MLY A 249 N ARG A 250 1555 1555 1.33 LINK C PHE A 272 N MLY A 273 1555 1555 1.33 LINK C MLY A 273 N GLU A 274 1555 1555 1.33 LINK C GLU A 276 N MSE A 277 1555 1555 1.34 LINK C MSE A 277 N ARG A 278 1555 1555 1.33 LINK C ASP A 292 N MSE A 293 1555 1555 1.32 LINK C MSE A 293 N MLY A 294 1555 1555 1.33 LINK C MLY A 294 N THR A 295 1555 1555 1.34 LINK C ASN A 300 N MLY A 301 1555 1555 1.33 LINK C MLY A 301 N ASN A 302 1555 1555 1.32 SITE 1 AC1 4 ARG A 171 ARG A 175 HOH A 360 HOH A 453 SITE 1 AC2 4 GLY A 158 MLY A 161 HOH A 507 HOH A 668 SITE 1 AC3 3 MLY A 9 MLY A 185 HOH A 677 SITE 1 AC4 30 GLY A 22 THR A 23 TYR A 24 ASP A 50 SITE 2 AC4 30 TYR A 55 LYS A 84 HIS A 117 SER A 166 SITE 3 AC4 30 ASN A 167 GLN A 190 TYR A 216 GLY A 217 SITE 4 AC4 30 ALA A 218 LEU A 219 GLY A 220 THR A 221 SITE 5 AC4 30 GLN A 222 TYR A 224 LEU A 236 ALA A 253 SITE 6 AC4 30 ALA A 269 GLN A 270 GLU A 276 GLU A 279 SITE 7 AC4 30 ASN A 280 MRD A 328 HOH A 353 HOH A 390 SITE 8 AC4 30 HOH A 567 HOH A 625 SITE 1 AC5 6 TYR A 55 HIS A 117 TYR A 118 TRP A 227 SITE 2 AC5 6 PHE A 310 NAD A 327 CRYST1 157.506 47.206 47.100 90.00 94.98 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.006349 0.000000 0.000554 0.00000 SCALE2 0.000000 0.021184 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021312 0.00000 MASTER 369 0 37 17 11 0 13 6 0 0 0 25 END